HUMA250117C1000
- 0.00
- 0.000.00%
Humacyte Newsroom
Express News | D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
Humacyte Provides Update on Commerical Launch, Pricing of Symvess
Humacyte Analyst Ratings
Express News | Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (Acellular Tissue Engineered Vessel-Tyod) for Extremity Vascular Trauma
Humacyte Provides Update on Commercial Launch and Pricing of Symvess (Acellular Tissue Engineered Vessel-tyod) for Extremity Vascular Trauma
Individual Investors Who Own 46% Along With Institutions Invested in Humacyte, Inc. (NASDAQ:HUMA) Saw Increase in Their Holdings Value Last Week
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday
Humacyte Is Maintained at Buy by Benchmark
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $17
Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Ligand Pharma (LGND)
Express News | Humacyte Inc : Benchmark Raises Target Price to $17 From $15
12 Health Care Stocks Moving In Friday's Pre-Market Session
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $15
Aptose APTO NASDAQ Compliance; Humacyte HUMA Full Approval
Humacyte's Symvess Gains FDA Approval and Positions for Market Success
Humacyte HUMA Approval; Molecular MTEM Notice of Delisting
BTIG Sticks to Their Buy Rating for Humacyte (HUMA)
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher